A novel vaccine evaluation platform to support SARS-CoV-2 vaccine development in resource-limiting settings
- Funded by BIRAC
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AFunder
BIRACPrincipal Investigator
Nimesh GuptaResearch Location
IndiaLead Research Institution
National Institute of Immunology, New DelhiResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnosticsResearch Subcategory
Disease modelsSpecial Interest Tags
N/AStudy Type
Non-ClinicalClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable
Abstract
The aim is to provide the human ACE2 expressing animal model for pre-clinical vaccine evaluation and to develop the Tcell and B-cell based assays that would test the immunogenicity, quality and stability of protective immune response to a SARS-CoV-2 vaccine candidate. Moreover, SARS-CoV-2 Pseudotyped virus has been developed for vaccine evaluation in BSL-2 settings.